Immunome Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
On October 2, 2026, Bristol-Myers Squibb Company purchased 4,425,487 shares of Immunome common stock (approximately 3.9% of outstanding shares as of June 30, 2026: 113.4M shares) as partial consideration for Amendment No. 4 to their existing License Agreement dated November 29, 2017. Concurrently, BMS paid Immunome $20 million in cash and assigned certain patent rights (Transferred Patents, detailed in redacted Exhibit A) to Immunome. In exchange, Immunome granted BMS a perpetual, non-exclusive license under the Transferred Patents for molecules other than Immunome's Licensed Compounds and Licensed Products. The amendment significantly narrows Immunome's obligations: it eliminates milestone payments, royalty payments, development/commercialization diligence, and sales reporting requirements, and terminates BMS's patent rights license effective immediately.
Why this rating
Material transaction (~$20M cash = 2.7% of $728.5M market cap; shares ~3.9% dilution) with strategic IP realignment. Removes future royalty/milestone obligations but also narrows Immunome's license scope. Moderate positive (cash inflow, patent ownership) offset by license narrowing and equity dilution. Significance reflects size relative to company and strategic IP implications, not sentiment alone.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.